Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

January 13, 2021

Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma

January 11, 2021

Harpoon Therapeutics Announces Closing of Public Offering of Common Stock

January 6, 2021

Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

January 6, 2021

Harpoon Therapeutics Announces Proposed Public Offering of Common Stock

January 4, 2021

Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

December 8, 2020

Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs

December 7, 2020

Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

November 16, 2020

Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

November 12, 2020

Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting

November 9, 2020

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2021. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations